A temperature sensitive live-attenuated canine influenza virus H3N8 vaccine

Nogales, A., Rodriguez, L., Chauché, C. , Huang, K., Reilly, E. C., Topham, D. J., Murcia, P. R. , Parrish, C. R. and Martínez-Sobrido, L. (2017) A temperature sensitive live-attenuated canine influenza virus H3N8 vaccine. Journal of Virology, 91(4), e02211-16. (doi:10.1128/JVI.02211-16) (PMID:27928017) (PMCID:PMC5286902)

[img]
Preview
Text
132980.pdf - Accepted Version

2MB

Abstract

Canine influenza is a respiratory disease of dogs caused by canine influenza virus (CIV). CIV subtypes responsible for influenza in dogs include H3N8, which originated from the transfer of H3N8 equine influenza virus to dogs; and the H3N2 CIV, which is an avian-origin virus that adapted to infect dogs. Influenza infections are most effectively prevented through vaccination to reduce transmission and future infection. Currently, only inactivated influenza vaccines (IIVs) are available for the prevention of CIV in dogs. However, the efficacy of IIVs is suboptimal, and novel approaches are necessary for the prevention of disease caused by this canine respiratory pathogen. Using reverse genetics techniques, we have developed a live-attenuated CIV vaccine (LACIV) for the prevention of H3N8 CIV. The H3N8 LACIV replicates efficiently in canine cells at 33°C but is impaired at temperatures of 37 to 39°C and was attenuated compared to wild-type H3N8 CIV in vivo and ex vivo. The LACIV was able to induce protection against H3N8 CIV challenge with a single intranasal inoculation in mice. Immunogenicity and protection efficacy were better than that observed with a commercial CIV H3N8 IIV but provided limited cross-reactive immunity and heterologous protection against H3N2 CIV. These results demonstrate the feasibility of implementing a LAIV approach for the prevention and control of H3N8 CIV in dogs and suggest the need for a new LAIV for the control of H3N2 CIV. Importance: Two influenza A virus subtypes has been reported in dogs in the last 16 years: the canine influenza viruses (CIV) H3N8 and H3N2 of equine and avian origins, respectively. To date, only inactivated influenza vaccines (IIVs) are available to prevent CIV infections. Here, we report the generation of a recombinant, temperature-sensitive H3N8 CIV as a live-attenuated influenza vaccine (LAIV), which was attenuated in mice and dog tracheal, explants compared to CIV H3N8 wild type. A single dose of H3N8 LACIV showed immunogenicity and protection against a homologous challenge that was better than that conferred with an H3N8 IIV, demonstrating the feasibility of implementing a LAIV approach for the improved control of H3N8 CIV infections in dogs.

Item Type:Articles
Additional Information:This research was partially funded by the University of Rochester Technology Development Fund to L.M.-S. and C.R.P. C.C. was supported by the Horserace Betting Levy Board, and P.R.M. was supported by the Medical Research Council of the United Kingdom (grant MC_UU_120/14/9).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Chauche, Dr Caroline and Murcia, Dr Pablo
Authors: Nogales, A., Rodriguez, L., Chauché, C., Huang, K., Reilly, E. C., Topham, D. J., Murcia, P. R., Parrish, C. R., and Martínez-Sobrido, L.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
College of Medical Veterinary and Life Sciences > School of Veterinary Medicine
Journal Name:Journal of Virology
Publisher:American Society for Microbiology
ISSN:0022-538X
ISSN (Online):1098-5514
Published Online:07 December 2016
Copyright Holders:Copyright © 2016 Nogales et al.
First Published:First published in Journal of Virology 91(4):e02211-16
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record